Inactive Instrument

ProMIS Neurosciences, Inc. Stock price Toronto S.E.

Equities

PMN

CA74346M4065

Biotechnology & Medical Research

Sales 2023 * - Sales 2024 * - Capitalization 48.86M 36.07M
Net income 2023 * -17M -12.55M Net income 2024 * -28M -20.67M EV / Sales 2023 * -
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * -
P/E ratio 2023 *
-1.78 x
P/E ratio 2024 *
-1.87 x
Employees 7
Yield 2023 *
-
Yield 2024 *
-
Free-Float 76.77%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 21-05-12
Founder 72 04-01-22
Chairman 64 15-06-28
Members of the board TitleAgeSince
Director/Board Member 86 14-03-07
Founder 72 04-01-22
Chief Executive Officer 61 21-05-12
More insiders
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
More about the company
  1. Stock
  2. Equities
  3. Stock ProMIS Neurosciences, Inc.
  4. Stock ProMIS Neurosciences, Inc. - Toronto S.E.